Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and Common Among Patients with HER2+ Breast Cancer.

Autor: Tchou J; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Julia.tchou@pennmedicine.upenn.edu.; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Julia.tchou@pennmedicine.upenn.edu., Gottipati S; Department of Surgery, University of California San Francisco, San Francisco, CA, USA., Goldbach M; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Baxter M; Department of Surgery, University of California San Francisco, San Francisco, CA, USA., Venters S; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA., Balassanian R; Department of Pathology, University of California San Francisco, San Francisco, CA, USA., Vohra P; Department of Pathology, University of California San Francisco, San Francisco, CA, USA., Gonzalves D; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Ahmad Z; Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Nayak A; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Boughey JC; Department of Surgery, Mayo Clinic, Rochester, MN, USA., Mukhtar RA; Department of Surgery, University of California San Francisco, San Francisco, CA, USA., Chen YY; Department of Pathology, University of California San Francisco, San Francisco, CA, USA.

Publikováno v: Annals of surgical oncology [Ann Surg Oncol] 2024 Nov; Vol. 31 (12), pp. 8093-8101. Date of Electronic Publication: 2024 Aug 08.

355P Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial

Autor: DeMichele, A., Price, E., Venters, S., Li, W., Wolf, D., Gibbs, J., Brown-Swigart, L., Klein, M., Onishi, N., Yau, C., Yee, D., Isaacs, C., Perlmutter, J., Rugo, H.S., Veer, L.J. Van't, Boughey, J., Symmans, F., Hylton, N., Esserman, L.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S325-S325

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.

Autor: O'Grady N; Department of Surgery, University of California San Francisco, San Francisco, California, USA., Gibbs DL; Shmulevich Lab, Institute for Systems Biology, Seattle, Washington, USA.; ISB-CGC, Seattle, Washington, USA., Abdilleh K; General Dynamics, Department of Information Technology (GDIT), Rockville, Maryland, USA.; ISB-CGC, Seattle, Washington, USA., Asare A; Department of Surgery, University of California San Francisco, San Francisco, California, USA., Asare S; Quantum Leap Healthcare Collaborative, San Francisco, California, USA., Venters S; Department of Surgery, University of California San Francisco, San Francisco, California, USA., Brown-Swigart L; Department of Surgery, University of California San Francisco, San Francisco, California, USA., Hirst GL; Department of Surgery, University of California San Francisco, San Francisco, California, USA., Wolf D; Department of Surgery, University of California San Francisco, San Francisco, California, USA., Yau C; Department of Surgery, University of California San Francisco, San Francisco, California, USA., van 't Veer LJ; Department of Surgery, University of California San Francisco, San Francisco, California, USA., Esserman L; Department of Surgery, University of California San Francisco, San Francisco, California, USA., Basu A; Department of Surgery, University of California San Francisco, San Francisco, California, USA.

Publikováno v: JAMIA open [JAMIA Open] 2021 Jun 03; Vol. 4 (2), pp. ooab038. Date of Electronic Publication: 2021 Jun 03 (Print Publication: 2021).

Neoadjuvant Endocrine Therapy Compared to Neoadjuvant Chemotherapy in Node‐Positive HR+, HER2− Breast Cancer (Nodal pCR and the Rate of ALND): A Systematic Review and Meta‐Analysis.

Autor: Vasigh, Mahtab^1,2,3 mvasigh1@jh.edu, Karoobi, Mohammadreza², Williams, Austin D.¹, Abreha, Fasika Molla⁴, Bleicher, Richard J.¹, Yazd, Seyed Mostafa Meshkati², Shamsi, Tahereh², Omranipour, Ramesh³, Elahi, Ahmad^3,5, Farhat, David⁴, Habibi, Mehran⁶, Sahgal, Pranshu

Publikováno v: Breast Journal. 8/1/2024, Vol. 2024, p1-12. 12p.

Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2‐Positive Breast Cancer.

Autor: Duan, Ningjun¹ (AUTHOR) duanningjun@jsph.org.cn, Hua, Yijia¹ (AUTHOR), Yan, Xueqi¹ (AUTHOR), He, Yaozhou¹ (AUTHOR), Zeng, Tianyu¹ (AUTHOR), Gong, Jue¹ (AUTHOR), Fu, Ziyi¹ (AUTHOR), Li, Wei¹ (AUTHOR), Yin, Yongmei¹ (AUTHOR) ymyin@njmu.edu.cn

Publikováno v: Advanced Science. May2024, Vol. 11 Issue 18, p1-15. 15p.